Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

1457403

USP

Naproxen sodium

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

(S)-6-Methoxy-α-methyl-2-naphthaleneacetic acid sodium salt

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C14H13NaO3
Numéro CAS:
26159-34-2
Poids moléculaire :
252.24
Numéro MDL:
MFCD00058507
Code UNSPSC :
41116107
ID de substance PubChem :
329750531
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

naproxen

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

[Na+].COc1ccc2cc(ccc2c1)[C@H](C)C([O-])=O

InChI

1S/C14H14O3.Na/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10;/h3-9H,1-2H3,(H,15,16);/q;+1/p-1/t9-;/m0./s1

Clé InChI

CDBRNDSHEYLDJV-FVGYRXGTSA-M

Informations sur le gène

human ... PTGS1(5742) , PTGS2(5743)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Naproxen sodium USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Naproxen Sodium and Pseudoephedrine Hydrochloride Extended-Release Tablets
  • Naproxen Sodium Tablets

Actions biochimiques/physiologiques

Cyclooxygenase (Prostaglandin H synthase 1 and 2) inhibitor.

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

PHR1040

Naproxen, Pharmaceutical Secondary Standard; Certified Reference Material

1457301

Naproxen, United States Pharmacopeia (USP) Reference Standard

N0250000

Naproxen, European Pharmacopoeia (EP) Reference Standard

Y0000399

Naproxen (racemic), European Pharmacopoeia (EP) Reference Standard

Y0000631

Naproxen impurity L, European Pharmacopoeia (EP) Reference Standard

1457312

Naproxen Related Compound A, United States Pharmacopeia (USP) Reference Standard

1457425

Naproxen Related Compound L, United States Pharmacopeia (USP) Reference Standard

08129

6-Methoxy-2-naphthol, pharmaceutical impurity standard

79584

2-Ethyl-6-methoxynaphthalene, pharmaceutical impurity standard

80713

(1RS)-1-(6-Methoxynaphthalen-2-yl)ethanol, pharmaceutical impurity standard

82170

(R)-Naproxen, pharmaceutical impurity standard

07506

(S)-Naproxen ethyl ester, pharmaceutical impurity standard

80822

(S)-Naproxen methyl ester, pharmaceutical impurity standard

80816

(2S)-2-(5-Chloro-6-methoxynaphthalen-2-yl)propanoic acid, pharmaceutical impurity standard

80821

(2S)-2-(5-Iodo-6-methoxynaphthalen-2-yl)propanoic acid, pharmaceutical impurity standard

80818

(2S)-2-(5-Bromo-6-methoxynaphthalen-2-yl)propanoic acid, pharmaceutical impurity standard

07503

2-Bromo-6-methoxynaphthalene, pharmaceutical impurity standard

07499

2-Methoxynaphthalene, pharmaceutical impurity standard

07547

6-Methoxy-2-naphthoic acid, pharmaceutical impurity standard

BP435

Naproxen, British Pharmacopoeia (BP) Reference Standard

1457436

Naproxen Related Compound G, United States Pharmacopeia (USP) Reference Standard

PHR2254

Naproxen 1,2,3 Propanetriol Esters, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2256

Naproxen 1,3-Butylene Glycol Esters, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2219

Naproxen 1,2 Propylene Glycol Esters, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2248

Naproxen 2,3-Butylene Glycol Ester, pharmaceutical secondary standard

PHR2257

Naproxen Isopropyl Ester, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2524

Naproxen Impurity N, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2525

Naproxen Impurity M, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2527

Naproxen Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2526

Naproxen Impurity H, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2520

Naproxen Impurity B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2519

Naproxen Impurity C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2518

Naproxen Related Compound G, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2523

Naproxen Related Compound L, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2530

rac-Naproxen, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2517

Naproxen Related Compound K, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2521

Naproxen Impurity A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2522

Naproxen Impurity I, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2528

Naproxen Impurity F, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2529

Naproxen Impurity E, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogrammes

Health hazardExclamation mark
GHS08,GHS07

Mention d'avertissement

Danger

Mentions de danger

H302,H360

Classification des risques

Acute Tox. 4 Oral - Repr. 1A

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Arın Gül Dal et al.
Journal of analytical methods in chemistry, 2014, 352698-352698 (2014-10-09)
Simple and rapid capillary zone electrophoretic method was developed and validated in this study for the determination of piroxicam in tablets. The separation of piroxicam was conducted in a fused-silica capillary by using 10 mM borate buffer (pH 9.0) containing 10%
Matteo Morotti et al.
European journal of obstetrics, gynecology, and reproductive biology, 179, 63-68 (2014-06-27)
Evaluate patient satisfaction at 6-month treatment in women with symptomatic rectovaginal endometriosis and migraine without aura with (progestogen-only contraceptive pill, POP versus sequential combined oral contraceptives, COC) STUDY DESIGN: A patient preference trial including 144 women (82 in the group
Jason A Miranda et al.
PloS one, 9(8), e106108-e106108 (2014-08-27)
Sensory processing in the spinal cord during disease states can reveal mechanisms for novel treatments, yet very little is known about pain processing at this level in the most commonly used animal models of articular pain. Here we report a
Tarjinder Sahota et al.
Toxicology and applied pharmacology, 278(3), 209-219 (2014-03-29)
The assessment of safety in traditional toxicology protocols relies on evidence arising from observed adverse events (AEs) in animals and on establishing their correlation with different measures of drug exposure (e.g., Cmax and AUC). Such correlations, however, ignore the role
Jennifer Y Xie et al.
Pain, 155(8), 1659-1666 (2014-05-28)
Preclinical assessment of pain has increasingly explored operant methods that may allow behavioral assessment of ongoing pain. In animals with incisional injury, peripheral nerve block produces conditioned place preference (CPP) and activates the mesolimbic dopaminergic reward pathway. We hypothesized that
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique